Skip to main content
. 2022 Feb 15;5:132. doi: 10.1038/s42003-022-03078-5

Fig. 4. Cholesterol efflux from M-Jak2 KO WT BMDM with LXR agonist.

Fig. 4

a–c mRNA level of ABCA1, ABCG1, and SCARB1 in BMDM under basal conditions, after loading with oxLDL or after loading with oxLDL and treating with TO901317 with ApoA1 to induce efflux (n = 10–19/group). d, e Cholesterol efflux from BMDM of M-Jak2 KO and WT mice treated with the LXR agonist, TO901317 in response to ApoB-depleted plasma (n = 8/group) and to purified ApoA1 (n = 8/group). f–i Representative en face images of Oil-red-O-stained lesser curvature of the aortic arch from M-Jak2 KO and WT mice treated with TO901317 or vehicle while on HCD for 3 weeks starting at 6 weeks of age. Scale bar, 1 mm (j) and their quantification (n = 4–9/group). Statistical analysis: a–e two-way ANOVA with Tukey’s multiple comparisons and (j) multiple t tests with Holm–Sidak correction were performed. Data are presented as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. See also Supplementary Fig. S11.